REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
Óstáilte ar MSN

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

Replimune provides update on FDA meeting

Replimune Group (NASDAQ:REPL) on Thursday said it held a Type A meeting with the U.S. Food and Drug Administration [FDA] on September 16 to discuss the complete response letter [CRL] for the company’s ...
The Globe and Mail

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with ...
TypePad

Elder Law Prof Blog

On February 16, 2024, my law school, Penn State Dickinson Law, hosted its monthly session on Race and Equal Protection of the Law (REPL) and this time our focus was on the search for equity in aging.